## List of Figures

<table>
<thead>
<tr>
<th>Fig. No.</th>
<th>Caption</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Structures of Raltegravir and Zibotentan, drugs that are in late stage clinical development</td>
</tr>
<tr>
<td>1.2</td>
<td>2-(5-Trifluoromethyl) pyridyloxy methyl-containing 1,3,4-oxadiazole derivatives</td>
</tr>
<tr>
<td>1.3</td>
<td>5-[(2-Disubstitutedamino-6-methyl-pyrimidin-4-yl)-sulfanyl methyl]-3H-1,3,4-oxadiazole-2-thiones</td>
</tr>
<tr>
<td>1.4</td>
<td>3-Acetyl-2-substituted phenyl-5-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1,3,4-oxadiazole</td>
</tr>
<tr>
<td>1.5</td>
<td>(E)-α-(Methoxyimino)-benzene acetate derivatives containing 1,3,4-oxadiazole</td>
</tr>
<tr>
<td>1.6</td>
<td>5-(3,4,5-Trimethoxyphenyl)-2-sulfonyl-1,3,4-oxadiazole derivatives</td>
</tr>
<tr>
<td>1.7</td>
<td>2, 4-Dichloro-5-fluorophenyl containing oxadiazoles</td>
</tr>
<tr>
<td>1.8</td>
<td>S-Substituted phenacetyl-1,3,4-oxadiazole derivative</td>
</tr>
<tr>
<td>1.9</td>
<td>5-Alkenyl-1,3,4-oxadiazole derivatives</td>
</tr>
<tr>
<td>1.10</td>
<td>2-Substituted-5-[isopropylthiazole] 1,3,4-oxadiazoles</td>
</tr>
<tr>
<td>1.11</td>
<td>Novel 1, 2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives</td>
</tr>
<tr>
<td>1.12</td>
<td>C-linked pyrazole biaryl tetrazoles</td>
</tr>
<tr>
<td>1.13</td>
<td>1,5-Diarylpyrazoles</td>
</tr>
<tr>
<td>1.14</td>
<td>1,3,5-Triaryl-4-alkylpyrazoles</td>
</tr>
<tr>
<td>1.15</td>
<td>Thiophene containing diarylpyrazoles</td>
</tr>
<tr>
<td>1.16</td>
<td>1-Aryl-3-(5-nitro-2-furyl)-4-arylpyrazoles</td>
</tr>
<tr>
<td>1.17</td>
<td>1,5-Diaryl and 1,3-diaryl substituted pyrazoles</td>
</tr>
<tr>
<td>1.18</td>
<td>Pyridine substituted pyrazoles</td>
</tr>
<tr>
<td>1.19</td>
<td>Novel N-phenyl pyrazole derivatives</td>
</tr>
<tr>
<td>1.20</td>
<td>N-phenyl-3-2-chlorophenyl substituted pyrazole derivatives</td>
</tr>
<tr>
<td>1.21</td>
<td>N-dichloro phenyl-pyrazole derivatives</td>
</tr>
</tbody>
</table>
1.22 1,2,4-Triazolo [3, 4-b]-1,3,4-thiadiazoles containing Pyrazole derivatives
1.23 2-[1-(5-Chloro-2-methoxy-phenyl)-5-methyl-1H-pyrazol-4-yl]-5-(substituted-phenyl)-[1,3,4] oxadiazoles.
1.24 Carbostyril derivatives of 1H-pyrazole
1.25 New pyrazole incorporated imidazole derivatives
1.26 Synthesis of novel pyrazole-sulfonamides
1.27 1,2,4-Traizole containing drugs
1.28 New Pyridine substituted 1,2,4-Triazole
1.29 3-Benzylsulfanyl derivatives of 1,2,4-triazole
1.30 Schiff and Mannich bases bearing 2,4-dichloro-5-fluorophenyl moiety
1.31 Thiazolidinone substituted triazole derivatives
1.32 3-[4-(4-substituted phenyl-5-thioxo-4,5-dihydro-1H-1,2,4 triazol-3-ylmethoxy)-phenyl]-2-phenyl-3H-quinazolin-4-one
1.33 Diphenyl-1,2,4-triazole-3-ones
1.34 N-(5-((1H-1,2,4-triazol-1-yl) methyl)-4-tertbutylthiazol-2-yl)-4-carboxamide derivatives
1.35 S-alkylated 1,2,4-triazoles incorporating biphenyl sulfone moiety
1.36 Quinoline derivatives carrying 1,2,4-triazole moiety
1.37 3, 6-disubstituted-1,2,4-triazolo-[3,4-b]-1,3,4- thiadiazoles
1.38 Some novel Ciprofloxacin containing 1,2,4-traizole analogues
1.39 2-(4-Methoxy-phenyl)-5-methyl-4-(2-arylsulfanyl-ethyl)-2, 4-dihydro-
[1,2,4] triazolo-3-ones
1.40 3-Biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles
1.41 Pyrazole containing 1,2,4-triazoles
1.42 New fungicidally active pyrazolyl-substituted 1,3,4-thiadiazoles
1.43 2-Sulfonamido/trifluoromethyl-6-substituted imidazo [2,1-b] [1,3,4] thiadiazole derivatives
1.44 N-(5-Benzylthio-1,3,4-thiadiazol-2-yl) and N-(5-benzylsulfonyl-1,3,4-
thiadiazol-2-yl) piperazinyl quinolone derivatives
1.45 2-Amino-substituted-1,3,4-thiadiazole
1.46 2-Amino-5-sulfanyl-1,3,4-thiadiazoles
1.47 1,3,4-Thiadiazole-piperidine carboxamide derivatives
1.48 1,3,4-Thiadiazole containing a Phenylalanine Moiety
1.49 2-Phenyl-5-phenylmethanesulfonylmethyl-substituted-[1,3,4] thiadiazole
1.50 2, 3-Dihydro-benzo [1,4] dioxine-6-carboxylic acid [5-(1-ethyl-propyl)-[1,3,4] thiadiazol-2-yl]-amide
1.51 3, 5-Diphenyl-substituted-3H-[1,3,4] thiadiazol-2-ylideneamine
1.52 5-[5-(5-Methyl-[1,3,4] thiadiazol-2-ylmethylsulfanyl)-[1,3,4] thiadiazol-2-ylsulfanyl methyl]-[1,3,4] thiadiazol-2-ylamine
1.53 3-(1,3,4-Thiadiazole-2-yl) quinoline derivatives
1.54 Imidazo [2,1-b]-1,3,4-thiadiazoles
1.55 Novel imidazo [2,1-b][1,3,4]thiadiazole carrying rhodanine-3-acetic acid.
2.1 Different isomeric forms of 1,3,4-oxadiazole
2.2 Reactions of 1,3,4-oxadiazoles with nucleophile
2.3 2-Naphthylxoxymethyl substituted 1,3,4-oxadiazoles
2.4 5- (4-Aroyl) -aryloxy methyl-2-thio-1,3,4-oxadiazoles
2.5 Dihydro-benzo [1, 4] dioxin-6-ylamino substituted 1,3,4-oxadiazoles
2.6 Some New Oxadiazoles derived from Phenylpropionohydrazides
2.7 Novel indolyl containing 1,3,4-oxadiazoles
2.8 3-Acetyl-2, 5-diaryl-2, 3-dihydro-1,3,4-oxadiazoles
2.9 Synthesis of some Novel 2,5-disubstituted 1,3,4-oxadiazoles
2.10 1, 5-Dimethyl-2-phenyl-4-[(5-(arylamino)-1,3,4-oxadiazol-2-yl] methylamino)-1, 2-dihydro-3H-pyrazol-3-one
2.11 $^1$H NMR spectrum of 2-(2-fluoro-4-methoxyphenyl)-5-[2-(trifluoromethyl) phenyl]-1,3,4-oxadiazole. (188c).
2.12 $^{13}$C NMR spectrum of 2-(2-fluoro-4-methoxyphenyl)-5-[2-(trifluoromethyl) phenyl]-1,3,4-oxadiazole. (188c).
2.13 LCMS spectrum of 2-(2-fluoro-4-methoxyphenyl)-5-[2-(trifluoromethyl) phenyl]-1,3,4-oxadiazole (188c).
2.14 $^1$H NMR spectrum of 2-chloro-5- [5-(2-fluoro-4-methoxyphenyl)-1,3,4-oxadiazol-2-yl] pyridine. (188f)
2.15 $^{13}$C NMR spectrum of 2-chloro-5- [5-(2-fluoro-4-methoxyphenyl)-1,3,4-
oxadiazol-2-yl] pyridine. (188f)

2.16 $^1$H NMR spectrum of 3-[5-(2-fluoro-4-methoxyphenyl)-1,3,4-oxadiazol-2-yl] quinoline (188j)

2.17 $^{13}$C NMR spectrum of 3-[5-(2-fluoro-4-methoxyphenyl)-1,3,4-oxadiazol-2-yl] quinoline (188j)

2.18 LC-MS spectrum of 3-[5-(2-fluoro-4-methoxyphenyl)-1,3,4-oxadiazol-2-yl] quinoline (188j)

2.19 Most potent compounds among the synthesized compounds

3.1 Structure of Pyrazole

3.2 Resonance structure of pyrazole

3.3 1-(4-phenyl)-N’-[4-Y-phenyl) methylene]-1H-pyrazole-4-carboxydrazides

3.4 Synthesis of 1-acetyl-3, 5-diphenyl-4, 5-dihydro-(1H)-pyrazole derivatives.

3.5 Novel Nitro-substituted Triaryl Pyrazole Derivatives

3.6 Synthesis of Pyrazole containing 4-hydroxy phenyl derivatives

3.7 Substituted 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.

3.8 Mannich bases derived from pyrazole and 1,2,4-triazoles

3.9 Synthesis of some new pyrazolo-[3, 4-d] pyrimidine derivatives

3.10 Synthesis of 1-(2, 4-dinitrophenyl)-3-aryl-4-(arylsulfanyl)-1H-Pyrazoles

3.11 N-(Substituted pyridinyl)-1-methyl (phenyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide derivatives.

3.12 Rhodanine-based 5-aryloxy pyrazoles


3.14 $^1$H NMR spectrum of 4-[4-(Ethoxycarbonyl)-5-phenyl-1H-pyrazol-1-yl] benzoic acid (241b)

3.15 NOESY spectrum of 4-[4-(Ethoxycarbonyl)-5-phenyl-1H-pyrazol-1-yl] benzoic acid (241b)

3.16 NOE spectrum of 4-[4-(Ethoxycarbonyl)-5-phenyl-1H-pyrazol-1-yl] benzoic acid (241b)
3.17 $^1$H NMR spectrum of ethyl 5-phenyl-1-quinolin-2-yl-$^1$H-pyrazole-4-carboxylate (241h).

3.18 $^{13}$C NMR spectrum of ethyl 5-phenyl-1-quinolin-2-yl-$^1$H-pyrazole-4-carboxylate. (241h).

3.19 IR spectrum of ethyl 5-phenyl-1-quinolin-2-yl-$^1$H-pyrazole-4-carboxylate (241h).

3.20 $^1$H NMR spectrum of ethyl 1-$^t$ert-butyl-5-phenyl-$^1$H-pyrazole-4-carboxylate (241j).

3.21 X-ray crystal structure of compound Ethyl 1-$^t$ert-butyl-5-phenyl-$^1$H-pyrazole-4-carboxylate (241j).

3.22 $^1$H NMR spectrum of (4-methylpiperezin-1-yl) [5-phenyl-1-(quinolin-2-yl)-1H-pyrazol-4-yl] methanone (243c).

3.23 $^{13}$C NMR spectrum of (4-methylpiperezin-1-yl) [5-phenyl-1-(quinolin-2-yl)-1H-pyrazol-4-yl] methanone (243c).

3.24 LCMS spectrum of (4-methylpiperezin-1-yl) [5-phenyl-1-(quinolin-2-yl)-1H-pyrazol-4-yl] methanone (243c).

3.25 $^1$H NMR spectrum of ethyl 1-cyclohexyl-5-(4-methoxyphenyl)-1H-pyrazole-4-carboxylate (246f).

3.26 $^{13}$C NMR spectrum of ethyl 1-cyclohexyl-5-(4-methoxyphenyl)-1H-pyrazole-4 carboxylate (246f).

3.27 X-ray crystal structure of compound ethyl 1-cyclohexyl-5-(4-methoxyphenyl)-1H-pyrazole-4 carboxylate (246f).

3.28 $^1$H NMR spectrum of {5-(4-methoxy Phenyl)-1-[4-(propan-2-yl) phenyl]-1H-pyrazol-4-yl} (morpholin-4-yl) methanone (248b).

3.29 $^{13}$C NMR spectrum of {5-(4-methoxy Phenyl)-1-[4-(propan-2-yl) phenyl]-1H-pyrazol-4-yl} (morpholin-4-yl)methanone. (248b).

3.30 LC MS spectrum of {5-(4-methoxy Phenyl)-1-[4-(propan-2-yl) phenyl]-1H-pyrazol-4-yl} (morpholin-4-yl) methanone (248b).

3.31 IR spectrum of {5-(4-methoxy Phenyl)-1-[4-(propan-2-yl) phenyl]-1H-pyrazol-4-yl} (morpholin-4-yl)methanone (248b).

3.32 $^1$H NMR spectrum of N-cyclopentyl-5-(4-methoxy phenyl-1-[4-(propan-2-yl) phenyl]-1H-pyrazole-4-carboxamide (248f).
13C NMR Spectrum of N-cyclopentyl-5-(4-methoxy phenyl-1-[4- (propan-2-yl) phenyl]-1H-pyrazole-4-carboxamide (248f).

Most potent compounds among the synthesized compounds 241(a-n)

Most potent compounds among the synthesized compounds 243(a-h)

Most potent compounds among the synthesized compounds 246 (a-l) and 248 (a-h)

Structure of 1,2,4-Triazole

Isomeric structure of 1,2,4-Triazole

3-(Substituted anilinomethyl)-4, 5-(substituted-2-furfurylidine) amono-1,2,4-triazole-5-thione derivative.

Mannich bases carrying 2, 4-Dichlorophenylfurfural Moiety

Triazole Compounds Containing 1,3-Dioxolane Rings

Thiazolo [3, 2-a] benzimidazole containing 1,2,4-Traizole moiety

4-Hydroxyphenyl substituted 1,2,4-Traizole-3-thiol derivatives

Mannich bases derived from Pyrazoles and 1,2,4-triazoles.

Fluorine containg 3, 5-disubstituted-4H-1,2,4-triazol-4-amines

Sulfone linked 1,2,4-triazole derivative

1H NMR spectrum of 4-(3-chloro phenyl)-5-(3, 4, 5-trimethoxyphenyl)-4H-1,2,4-triazole-3-thiol (292a).

13C NMR spectrum of 4-(3-chloro phenyl)-5-(3, 4, 5-trimethoxyphenyl)-4H-1,2,4-triazole-3-thiol (292a).

IR spectrum of 4-(3-chloro phenyl)-5-(3, 4, 5-trimethoxyphenyl)-4H-1,2,4-triazole- 3-thiol. (292a)

1H NMR spectrum of 4-(2, 5-dimethoxy phenyl)-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazole thiol (292g).

LCMS spectrum of 4-(2,5-dimethoxy phenyl)-5-(3, 4, 5-trimethoxyphenyl)-4H-1,2,4-triazole-3-thiol (292g).

1H NMR spectrum of 4-(3-Chlorophenyl)-3-(2, 6-difluoro-benzyl sulfanyl)-5-(3,4,5-trimethoxy-phenyl)-4H-[1,2,4]-triazole (293a).

13C NMR spectrum of 4-(3-Chlorophenyl)-3-(2, 6-difluoro-benzyl sulfanyl)-5-(3, 4, 5-trimethoxy-phenyl)-4H-[1,2,4]-triazole (293a).
4.18 LCMS spectrum of 4-(3-Chlorophenyl)-3-(2, 6-difluoro-benzyl sulfanyl)-5-(3, 4, 5-trimethoxy-phenyl)-4H-[1,2,4]-triazole (293a).

4.19 X-ray crystal structure for 293a

4.20 IR Spectrum of 4-(3-Chlorophenyl)-3-(2,6-difluoro-benzyl sulfanyl)-5-(3, 4, 5- trimethoxy-phenyl)-4H-[1,2,4]-triazole (293a).

4.21 $^1$H NMR spectrum of 4-(3-(trifluoro methyl) phenyl)-3-(2, 6-difluoro-benzyl sulfanyl)-5-(3,4,5 trimethoxy-phenyl)-4H-[1,2,4]-triazole (293c).

4.22 $^{13}$C NMR spectrum of 4-(3-(trifluoro methyl) phenyl)-3-(2, 6-difluoro-benzyl sulfanyl)-5-(3,4,5 trimethoxy-phenyl)-4H-[1,2,4]-triazole (293c).

4.23 LCMS spectrum of 4-(3-(trifluoro methyl) phenyl)-3-(2, 6-difluoro-benzyl sulfanyl)-5-(3,4,5 trimethoxy-phenyl)-4H-[1,2,4]-triazole (293c).

4.24 Most potent compounds among the synthesized compounds.

5.1 Different isomeric forms of 1,3,4-Thiadiazole

5.2 2, 5-Disubstituted-1,3,4-thiadiazoles

5.3 Substituted imidazothiadiazoles

5.4 Fatty acids containing 2, 5-disubstituted-1,3,4-thiadiazoles

5.5 Thiophene containing 1,3,4-thiadiazole

5.6 5-(4-Chlorophenyl)-1,3,4-Thiadiazole Sulfonamides

5.7 Novel 2-aralkyl-5-substituted-6-(4′-fluorophenyl)-imidazo [2,1-b] [1, 3,4] thiadiazole

5.8 1,3,4-thiadiazole-containing benzisoselenazolone derivatives

5.9 Arylideneamino-1,3,4-thiadiazole-(thio/dithio)-acetamido Cephalosporanic Acids

5.10 $^1$H NMR spectrum of 5-(4-Fluoro-3-nitro-phenyl)-[1,3,4] thiadiazole-2-ylamine (337)

5.11 $^1$H NMR spectrum of N-[5-(4-Fluoro-3-nitro-phenyl)-[1,3,4-thiaioal-2-yl]-2,2-dimethyl-propionamide (338)

5.12 $^1$H NMR spectrum of 2, 2-Dimethyl-N-[5-(4-morpholin-4-yl-3-nitro-phenyl)-[1,3,4]-thaidazo-2-yl]-propionamide (339a).

5.13 $^{13}$C NMR spectrum of 2, 2-Dimethyl-N-[5-(4-morpholin-4-yl-3-nitro-phenyl)-[1,3,4]-thaidazo-2-yl]-propionamide (339a).
5.14 IR Spectrum of 2, 2-Dimethyl-N-[5-(4-morpholin-4-yl-3-nitro-phenyl)-[1,3,4]-thiadazo-2-yl]-propionamide (339a).
5.15 LCMS spectrum of 2, 2-Dimethyl-N-[5-(4-morpholin-4-yl-3-nitro-phenyl)-[1,3,4]-thiadazo-2-yl]-propionamide (339a).
5.16 $^1$H NMR spectrum of 2, 2-Dimethyl-N-(5-{3-nitro-4-[4-(4-trifluoromethyl-phenyl)-piperdin-1-yl]-phenyl}-[1,3,4] thia diazol-2-yl)-propionamide (339c).
5.17 $^{13}$C NMR spectrum of 2, 2-Dimethyl-N-(5- {3-nitro-4-[4-(4-trifluoromethyl-phenyl)-piper din-1-yl]-phenyl}-[1,3,4] thia diazol-2-yl)-propion amide (339c).
5.18 LCMS spectrum of 2, 2-Dimethyl-N-(5- {3-nitro-4-[4-(4-trifluoromethyl-phenyl)-piper din-1-yl]-phenyl}-[1,3,4] thia diazol-2-yl)-propion amide (339c).
5.19 $^1$H NMR spectrum of 2-(4-Fluoro-3-nitro-phenyl)-6-(4-methoxy-phenyl)- imidazo [2, 1-b][1,3,4]thiadiazole. (340).
5.20 $^1$H NMR Spectrum of 6-(4-Methoxy-phenyl)-2-[4-morpholin-4-1-yl]-3-nitro-phenyl]-imidazo [2,1-b][1,3,4-thaidazole (341a).
5.21 $^{13}$C NMR spectrum of 6-(4-Methoxy-phenyl)-2-[4-morpholin-4-1-yl]-3-nitro-phenyl]-imidazo [2, 1-b][1,3,4-thaidazole (341a).
5.22 LCMS spectrum of 6-(4-Methoxy-phenyl)-2-[4-morpholin-4-1-yl]-3-nitro-phenyl]-imidazo [2,1-b][1,3,4-thaidazole (341a).
5.23 IR spectrum of 6-(4-Methoxy-phenyl)-2-[4-morpholin-4-1-yl]-3-nitro-phenyl]-imidazo [2,1-b][1,3,4-thaidazole (341a).
5.24 NOESY Spectrum of 6-(4-Methoxy-phenyl)-2-[4-morpholin-4-1-yl]-3-nitro-phenyl]-imidazo [2,1-b][1,3,4-thaidazole (341a).
5.25 Most potent compounds among the synthesized compounds